Cardiovascular Drugs and Therapy

, Volume 31, Issue 1, pp 53–61

Cardioprotection: Where to from here?

  • Robert A. Kloner
  • Sharon L. Hale
  • Wangde Dai
  • Jianru Shi

DOI: 10.1007/s10557-016-6691-0

Cite this article as:
Kloner, R.A., Hale, S.L., Dai, W. et al. Cardiovasc Drugs Ther (2017) 31: 53. doi:10.1007/s10557-016-6691-0


The size of the myocardial infarction remains an important therapeutic target, because heart attack size correlates with mortality and heart failure. In this era, myocardial infarct size is reduced primarily by timely reperfusion of the infarct related coronary artery. Whereas numerous pre-clinical studies have shown that certain pharmacologic agents and therapeutic maneuvers reduce myocardial infarction size greater than reperfusion alone, very few of these therapies have translated to successful clinical trials or standard clinical use. In this review we discuss both the recent successes as well as recent disappointments, and describe some of the newer potential therapies from the preclinical literature that have not yet been tested in clinical trials.


Acute myocardial infarction ST elevation myocardial infarction Myocardial infarct size reduction Beta blockade Adenosine Hypothermia 

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Cardiovascular Research InstituteHuntington Medical Research InstitutesPasadenaUSA
  2. 2.Division of Cardiovascular Medicine, Department of MedicineKeck School of Medicine at University of Southern CaliforniaLos AngelesUSA

Personalised recommendations